Education
About Us
Working with TipRanks
Follow Us
Guard Therapeutics International AB (DE:5LH0)
FRANKFURT:5LH0
5LH0 Stock Chart & Stats
€0.04
€0.06(3.57%)
At close: 4:00 PM EST
€0.04
€0.06(3.57%)
Day’s Range― - ―
52-Week Range€0.01 - €2.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.00M
Enterprise Value-€15.54M
Total Cash (Recent Filing)€100.48M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding20,167,631
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No DebtThe absence of recorded debt reduces mandatory interest and refinancing obligations, preserving strategic optionality across long clinical timelines. This lowers immediate cash drain and financial distress risk, allowing management to focus capital on development milestones rather than servicing debt.
Focused Kidney Disease PipelineA concentrated R&D mandate on AKI and renal indications creates a clear strategic thesis and specialization. Focused expertise can improve trial design, attract targeted collaborators and payers, and support a differentiated clinical and commercial positioning if the pipeline advances.
Lean Operating StructureA small headcount implies a lean cost base and lower fixed overhead, which can extend runway per funding round. For a clinical-stage biotech, this allows flexible outsourcing of trials and manufacturing and can improve capital efficiency while programs are advanced.
Bears Say
No Revenue; Persistent LossesAbsence of any revenue through 2025 and continued large losses means the company lacks commercial cash generation. Long-term viability depends on external financing; this structural revenue gap raises sustained execution and funding risk until commercialization is achieved.
Depleted Equity And AssetsMaterial erosion of equity and assets over a few years weakens the balance sheet buffer against clinical or development setbacks. Reduced capital base limits financial flexibility, increases sensitivity to adverse events, and heightens likelihood of dilutive financing needs.
Heavy Negative Operating Cash FlowSustained and large negative operating cash flow demonstrates ongoing cash consumption tied to operations and development. This persistent burn requires frequent external capital, increasing financing risk, potential dilution, or program pacing compromises over the medium term.
5LH0 FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was €0.01 and its highest was €2.27 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is €3.00M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is May 13, 2026 which is in 79 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Feb 20, 2026. The company reported -€0.076 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.076.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -€0.076 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in DE:5LH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―